• 제목/요약/키워드: Early Dementia

검색결과 153건 처리시간 0.025초

Enhancing Alzheimer's Disease Classification using 3D Convolutional Neural Network and Multilayer Perceptron Model with Attention Network

  • Enoch A. Frimpong;Zhiguang Qin;Regina E. Turkson;Bernard M. Cobbinah;Edward Y. Baagyere;Edwin K. Tenagyei
    • KSII Transactions on Internet and Information Systems (TIIS)
    • /
    • 제17권11호
    • /
    • pp.2924-2944
    • /
    • 2023
  • Alzheimer's disease (AD) is a neurological condition that is recognized as one of the primary causes of memory loss. AD currently has no cure. Therefore, the need to develop an efficient model with high precision for timely detection of the disease is very essential. When AD is detected early, treatment would be most likely successful. The most often utilized indicators for AD identification are the Mini-mental state examination (MMSE), and the clinical dementia. However, the use of these indicators as ground truth marking could be imprecise for AD detection. Researchers have proposed several computer-aided frameworks and lately, the supervised model is mostly used. In this study, we propose a novel 3D Convolutional Neural Network Multilayer Perceptron (3D CNN-MLP) based model for AD classification. The model uses Attention Mechanism to automatically extract relevant features from Magnetic Resonance Images (MRI) to generate probability maps which serves as input for the MLP classifier. Three MRI scan categories were considered, thus AD dementia patients, Mild Cognitive Impairment patients (MCI), and Normal Control (NC) or healthy patients. The performance of the model is assessed by comparing basic CNN, VGG16, DenseNet models, and other state of the art works. The models were adjusted to fit the 3D images before the comparison was done. Our model exhibited excellent classification performance, with an accuracy of 91.27% for AD and NC, 80.85% for MCI and NC, and 87.34% for AD and MCI.

해녀 우울장애 환자의 임상적 특징 (Clinical Characteristics of Haenyeo with Depressive Disorders)

  • 박준혁;전병선;이창인;김문두;정지운;정영은
    • 생물정신의학
    • /
    • 제23권2호
    • /
    • pp.63-68
    • /
    • 2016
  • Objectives Haenyeo are Korean professional women breath-hold divers in Jeju island. The aim of this study was to investigate the clinical characteristics of depressed Haenyeo group, compared to non-Haenyeo depressed group. Methods This study included 75 Haenyeo and 340 non-Haenyeo with depressive disorders recruited from the Dementia Early Detection Program in Jeju island. Structural diagnostic interviews were performed using the Korean version of Mini International Neuropsychiatric Interview. All patients completed the questionnaires, including the Subjective Memory Complaints Questionnaire (SMCQ), the Patient Health Questionnaire-15 (PHQ-15), and the Blessed dementia scale. Depression was evaluated by the Korean version of short form the Geriatric Depression Scale (K-SGDS) and cognition was assessed by the Korean version of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) assessment packet. Results Although the mean scores of the K-SGDS were similar between Haenyeo and non-Haenyeo depressed groups, the Haenyeo group showed a higher mean score on the PSQ-15 (p < 0.001, ANCOVA adjusting for age, the K-SGDS and education). The Haenyeo group showed poorer performance on the Korean Version of Frontal Assessment Batter (p < 0.001), the Mini-Mental State Examination in the Korean version of the CERAD Assessment Packet (p < 0.018), the word fluency test (p < 0.001), and the word list memory test (p = 0.012) in ANCOVA adjusting for age and education. The mean SMCQ score was higher in the Haenyeo depressed group than in the non-Haenyeo depressed group. Conclusions The Haenyeo depressed group shows cognitive dysfunction, especially frontal lobe dysfunction, compared to the non-Haenyeo depressed group, indicating the Haenyeo depressed group may have more severe frontolimbic dysfunction due to chronic exposure to hypoxia. The Haenyeo depressed group suffers more somatic symptoms than the non-Haenyeo depressed group.

알츠하이머병에서 행동심리증상과 간병인의 부양부담 사이의 상관관계 (Correlation between Behavioral Psychological Symptoms and Caregiver Burden in Alzheimer's Disease)

  • 김요섭;이강준;김현
    • 정신신체의학
    • /
    • 제24권2호
    • /
    • pp.200-207
    • /
    • 2016
  • 연구목적 알츠하이머병은 대표적인 증상인 인지 기능의 저하 외에도 다양한 행동심리증상(Behavioral Psychological Symptoms of Dementia, BPSD)을 흔히 동반하며, 이는 간병인들로 하여금 부양 부담을 야기한다. 본 연구에서는 한국의 치매 환자들과 그들의 간병인들을 대상으로 행동심리증상의 각 항목들과 간병인의 부양 부담에 대한 상관관계를 알아보고자 한다. 방 법 80명의 치매 환자들을 대상으로 행동심리증상을 한국형 신경정신행동검사(Korean neuropsychiatric inventory, K-NPI)를 통해서 평가하였고, 부양자들의 부양부담은 한국판 Zarit Burden Interview(ZBI)를 이용하여 평가하였다. 결 과 K-NPI의 망상, 환각, 초조/공격성, 우울/낙담, 불안, 탈억제, 과민/불안정 빈도와 간병인 부양부담의 평가척도인 ZBI 사이에 통계적으로 유의한 상관이 있었으며, K-NPI의 환각, 초조/공격성, 불안, 탈억제, 이상운동증상, 수면/야간행동의 심각도와 ZBI 척도 간에 유의한 상관이 있었다. K-NPI의 빈도${\times}$심각도 영역에서는 망상, 환각, 초조/공격성, 우울/낙담, 불안, 탈억제, 이상운동증상, 수면/야간행동과 ZBI가 유의한 상관관계를 보였다. 또한 인지기능척도(MMSE-KC, CDR, GDS)와 ZBI 척도 사이에 유의한 상관이 있었으며, 일상생활수행능력(Barthel-ADL, K-ADL)과 ZBI 척도 사이에도 유의한 상관관계를 보였다. 결 론 알츠하이머병 환자의 BPSD와 간병인의 부양부담과 상관관계가 있었다. 또한 간병인의 부양부담은 인지기능 및 일상생활수행능력과도 상관이 있었다. BPSD를 조기에 발견하고 적절하게 치료함으로써 치매 환자의 삶뿐만 아니라 보호자의 삶의 질도 개선시킬 수 있을 것이다.

Month and Season of Birth as a Risk Factor for Alzheimer's Disease: A Nationwide Nested Case-control Study

  • Tolppanen, Anna-Maija;Ahonen, Riitta;Koponen, Marjaana;Lavikainen, Piia;Purhonen, Maija;Taipale, Heidi;Tanskanen, Antti;Tiihonen, Jari;Tiihonen, Miia;Hartikainen, Sirpa
    • Journal of Preventive Medicine and Public Health
    • /
    • 제49권2호
    • /
    • pp.134-138
    • /
    • 2016
  • Objectives: Season of birth, an exogenous indicator of early life environment, has been related to higher risk of adverse psychiatric outcomes but the findings for Alzheimer's disease (AD) have been inconsistent. We investigated whether the month or season of birth are associated with AD. Methods: A nationwide nested case-control study including all community-dwellers with clinically verified AD diagnosed in 2005 to 2012 (n=70 719) and up to four age- sex- and region of residence-matched controls (n=282 862) residing in Finland. Associations between month and season of birth and AD were studied with conditional logistic regression. Results: Month of birth was not associated with AD (p=0.09). No strong associations were observed with season (p=0.13), although in comparison to winter births (December-February) summer births (June-August) were associated with higher odds of AD (odds ratio, 1.03; 95% confidence interval, 1.00 to 1.05). However, the absolute difference in prevalence in winter births was only 0.5% (prevalence of those born in winter were 31.7% and 32.2% for cases and controls, respectively). Conclusions: Although our findings do not support the hypothesis that season of birth is related to AD/dementia risk, they do not invalidate the developmental origins of health and disease hypothesis in late-life cognition. It is possible that season does not adequately capture the early life circumstances, or that other (postnatal) risk factors such as lifestyle or socioeconomic factors overrule the impact of prenatal and perinatal factors.

Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies

  • Kang, Ju-Hee;Ryoo, Na-Young;Shin, Dong Wun;Trojanowski, John Q.;Shaw, Leslie M.
    • The Korean Journal of Physiology and Pharmacology
    • /
    • 제18권6호
    • /
    • pp.447-456
    • /
    • 2014
  • Until now, a disease-modifying therapy (DMT) that has an ability to slow or arrest Alzheimer's disease (AD) progression has not been developed, and all clinical trials involving AD patients enrolled by clinical assessment alone also have not been successful. Given the growing consensus that the DMT is likely to require treatment initiation well before full-blown dementia emerges, the early detection of AD will provide opportunities to successfully identify new drugs that slow the course of AD pathology. Recent advances in early detection of AD and prediction of progression of the disease using various biomarkers, including cerebrospinal fluid (CSF) $A{\beta}_{1-42}$, total tau and p-tau181 levels, and imagining biomarkers, are now being actively integrated into the designs of AD clinical trials. In terms of therapeutic mechanisms, monitoring these markers may be helpful for go/no-go decision making as well as surrogate markers for disease severity or progression. Furthermore, CSF biomarkers can be used as a tool to enrich patients for clinical trials with prospect of increasing statistical power and reducing costs in drug development. However, the standardization of technical aspects of analysis of these biomarkers is an essential prerequisite to the clinical uses. To accomplish this, global efforts are underway to standardize CSF biomarker measurements and a quality control program supported by the Alzheimer's Association. The current review summarizes therapeutic targets of developing drugs in AD pathophysiology, and provides the most recent advances in the clinical utility of CSF biomarkers and the integration of CSF biomarkers in current clinical trials.

알츠하이머병 진단에서 18F-Florbetaben의 유용성 (Usefulness of 18F-Florbetaben in Alzheimer's Disease Diagnosis)

  • 이효영;임인철;송민재;신성규
    • 한국방사선학회논문지
    • /
    • 제10권5호
    • /
    • pp.307-312
    • /
    • 2016
  • 알츠하이머병은 치매를 일으키는 가장 흔한 퇴행성 뇌 질환이다. 뇌에 축적되는 베타 아밀로이드 단백질은 기억력감퇴, 언어능력 저하등 일상생활 수행 능력이 어렵게 된다. 베타 아밀로이드 플라그 농도는 인지장애를 가진 성인환자에서 알츠하이머 질환과 인지장애의 다른 원인인지를 평가하는 데 사용된다. 베타아밀로이드 단백질에 대한 높은 민감성과 특이성을 가진 $^{18}F$-Florbetaben을 이용하여 알츠하이머병을 조기진단에 유용성을 알아보고자 한다. $^{18}F$-FDG Brain 영상에서 특이소견 없음을 보인다. 그리고 MR-Brain 영상에서 해마의 위축이 없는 것으로 보였다. 하지만 $^{18}F$-Florobetaben에서 베타 아밀로이드의 섭취는 알츠하이머병의 진전이 되고 있음을 알려준다. 따라서, $^{18}F$-Florobetaben은 알츠하이머병을 조기 진단하는 데 매우 유용하다.

MicroRNAs as Novel Biomarkers for the Diagnosis of Alzheimer's Disease and Modern Advancements in the Treatment

  • Gunasekaran, Tamil Iniyan;Ohn, Takbum
    • 대한의생명과학회지
    • /
    • 제21권1호
    • /
    • pp.1-8
    • /
    • 2015
  • Alzheimer's disease is a common form of dementia occurring among the elderly population and can be identified by symptoms such as cognition impairments, memory loss and neuronal dysfunction. Alzheimer's disease was found to be caused by the deposition of $\beta$-amyloid plaques and neurofibrillary tangles. In addition, mutation in the APP (Amyloid precursor protein), Presenilin 1 (PSEN1) and Presenilin 2 (PSEN2) genes were also found to contribute to Alzheimer's disease. Since the potential conformational diagnosis of Alzheimer's disease requires histopathological tests on brain through autopsy, potential early diagnosis still remains challenging. In recent years, several researches have proposed the use of biomarkers for early diagnosis. In cerebrospinal fluid (CSF), $\beta$-amyloid(1-42), phosphorylated-tau and total tau were suggested to be effective biomarkers for Alzheimer's disease diagnosis. However, a single biomarker might not be sufficient for potential diagnosis of Alzheimer's disease. Thus, the use of RNA interference (RNAi) through microRNAs (miRNAs) has been proposed by several researchers for simultaneous analysis of several biomarkers using microarray technology. These miRNA based biomarkers can be analysed from both blood and CSF, but miRNAs from blood are advantageous over CSF as they are non-invasive and simple for collection. Moreover, the RNAi based therapeutics by siRNA (short interference RNA) or shRNA (short hairpin RNA) have also been proposed to be effective in the treatment of Alzheimer's disease. This review describes the promising application of RNAi technology in therapeutics and as a biomarker for both Alzheimer's disease diagnosis and treatment.

Statistical Techniques based Computer-aided Diagnosis (CAD) using Texture Feature Analysis: Applied of Cerebral Infarction in Computed Tomography (CT) Images

  • Lee, Jaeseung;Im, Inchul;Yu, Yunsik;Park, Hyonghu;Kwak, Byungjoon
    • 대한의생명과학회지
    • /
    • 제18권4호
    • /
    • pp.399-405
    • /
    • 2012
  • The brain is the body's most organized and controlled organ, and it governs various psychological and mental functions. A brain abnormality could greatly affect one's physical and mental abilities, and consequently one's social life. Brain disorders can be broadly categorized into three main afflictions: stroke, brain tumor, and dementia. Among these, stroke is a common disease that occurs owing to a disorder in blood flow, and it is accompanied by a sudden loss of consciousness and motor paralysis. The main types of strokes are infarction and hemorrhage. The exact diagnosis and early treatment of an infarction are very important for the patient's prognosis and for the determination of the treatment direction. In this study, texture features were analyzed in order to develop a prototype auto-diagnostic system for infarction using computer auto-diagnostic software. The analysis results indicate that of the six parameters measured, the average brightness, average contrast, flatness, and uniformity show a high cognition rate whereas the degree of skewness and entropy show a low cognition rate. On the basis of these results, it was suggested that a digital CT image obtained using the computer auto-diagnostic software can be used to provide valuable information for general CT image auto-detection and diagnosis for pre-reading. This system is highly advantageous because it can achieve early diagnosis of the disease and it can be used as supplementary data in image reading. Further, it is expected to enable accurate medical image detection and reduced diagnostic time in final-reading.

일 지역 알츠하이머병 노인에서 Apolipoprotein E ${\varepsilon}4$와 인지변화의 연관에 대한 전향적 연구 (A Prospective Study on an Association between Apolipoprotein E ${\varepsilon}4$ and Cognitive Change in Community-Dwelling Elders with Alzheimer's Disease)

  • 강민성;문석우
    • 생물정신의학
    • /
    • 제20권3호
    • /
    • pp.104-110
    • /
    • 2013
  • Objectives : The aim of this study was to examine the prospective impact of the apolipoprotein E (APOE) ${\varepsilon}4$ on cognitive performance in the community-dwelling elderly individuals with Alzheimer's disease (AD). Methods : The total number of subjects was 30 (12 men and 18 women) who were diagnosed with AD from a Korean project of "Early Detection of Dementia". People aged 65-85 years were included in the analysis. The eight neuropsychological domains from the Korean version of Consortium to Establish a Registry of Alzheimer's Disease (CERAD-K) were conducted to test subjects. They have been followed at 24-month intervals with the same assessments at each interval. Their cognitive performance at 2 year intervals was compared by the occurrence of the APOE ${\varepsilon}4$. Results : The impact of ${\varepsilon}4$ allele was significant in the Word List Memory Test (WLMT, F = 4.345, df = 1, p = 0.021) and Word List Recall Test (WLRT, F = 5.569, df = 1, p = 0.033). Conclusions : The APOE ${\varepsilon}4$ allele was significantly correlated especially with verbal episodic memory domain in community-dwelling elders diagnosed with AD.

I-123 MIBG Cardiac SPECT의 임상적 적응증 (Clinical Application of I-123 MIBG Cardiac Imaging)

  • 강도영
    • 대한핵의학회지
    • /
    • 제38권5호
    • /
    • pp.331-337
    • /
    • 2004
  • Cardiac neurotransmission imaging allows in vivo assessment of presynaptic reuptake, neurotransmitter storage and postsynaptic receptors. Among the various neurotransmitter, I-123 MIBG is most available and relatively well-established. Metaiodobenzylguanidine (MIBG) is an analogue of the false neurotransmitter guanethidine. It is taken up to adrenergic neurons by uptake-1 mechanism as same as norepinephrine. As tagged with I-123, it can be used to image sympathetic function in various organs including heart with planar or SPECT techniques. I-123 MIBG imaging has a unique advantage to evaluate myocardial neuronal activity in which the heart has no significant structural abnormality or even no functional derangement measured with other conventional examination. In patients with cardiomyopathy and heart failure, this imaging has most sensitive technique to predict prognosis and treatment response of betablocker or ACE inhibitor. In diabetic patients, it allow very early detection of autonomic neuropathy. In patients with dangerous arrhythmia such as ventricular tachycardia or fibrillation, MIBG imaging may be only an abnormal result among various exams. In patients with ischemic heart disease, sympathetic derangement may be used as the method of risk stratification. In heart transplanted patients, sympathetic reinnervation is well evaluated. Adriamycin-induced cardiotoxicity is detected earlier than ventricular dysfunction with sympathetic dysfunction. Neurodegenerative disorder such as Parkinson's disease or dementia with Lewy bodies has also cardiac sympathetic dysfunction. Noninvasive assessment of cardiac sympathetic nerve activity with I-123 MIBG imaging nay be improve understanding of the pathophysiology of cardiac disease and make a contribution to predict survival and therapy efficacy.